Article Text

Download PDFPDF
Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer
  1. Yulan Ren, MD, PhD*,
  2. Tingyan Shi, MD, PhD,
  3. Rong Jiang, MD*,,
  4. Sheng Yin, MD*,
  5. Pan Wang, MD* and
  6. Rongyu Zang, MD, PhD*,
  1. *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center; and
  2. Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Fudan University Zhongshan Hospital, Shanghai, China.
  1. Address correspondence and reprint requests to Rongyu Zang, MD, PhD, Department of Obstetrics and Gynecology, Fudan University Zhongshan Hospital, 180 Feng-Lin Rd, Shanghai 200032, China. E-mail: FudanGOG@gmail.com.

Abstract

Objective The aim of this study was to determine the impact of neoadjuvant chemotherapy (NACT) on survival in patients with bulky stage IIIC and IV epithelial ovarian cancer.

Methods Between January 2009 and December 2012, 408 patients with ovarian cancer with extensive upper abdominal disease were reviewed. On the basis of the cycle number of NACT, patients were divided into 2 groups, namely, primary debulking surgery (PDS) group, which included the patients who received no more than 1 cycle of NACT; and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) group, which included the patients who received more than 1 cycle of NACT. All patients underwent cytoreductive surgery with the goal of optimal outcome (⩽1 cm). Progression-free survival and overall survival were evaluated.

Results There was no difference in surgical outcomes between PDS and NACT-IDS group, which was evaluated with either complete cytoreduction (41/376, 10.9% vs 6/32, 18.8%) or optimal cytoreduction (201/376, 53.5% vs 18/32, 56.2%). The median survival was 43.0 and 27.3 months in the PDS group and NACT-IDS group, with an estimated 5-year survival of 36% and 31%, respectively (P = 0.032; hazard ratio, 0.59; 95% confidence interval, 0.36–0.95). Complete cytoreduction, without bowel mesenteric carcinomatosis, and no more than 1 cycle of NACT were associated with lengthened survival by the multivariate analysis (P = 0.012, 0.025, and 0.036, respectively).

Conclusions Neoadjuvant chemotherapy was associated with poor survival of patients with bulky stage IIIC and IV ovarian cancer. A well-designed randomized trial with a better quality control of surgical procedures is needed to confirm the results.

  • Ovarian cancer
  • Neoadjuvant chemotherapy
  • Primary debulking surgery
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

  • Yulan Ren and Tingyan Shi contributed equally as the first authors.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.